California is currently home to 5600 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234
Recruiting
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of single subcutaneous dose of AZD6234 with end stage renal disease, severe, and possibly moderate and mild renal impairment in comparison to a matched healthy control group.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/05/2025
Locations: Research Site, Lake Forest, California
Conditions: Renal Impairment
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
Recruiting
Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness o... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/05/2025
Locations: Takeda Site 11, Redwood City, California
Conditions: Idiopathic Hypersomnia
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
Recruiting
The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/05/2025
Locations: Vanda Investigational Site, Los Angeles, California
Conditions: Obesity
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
Recruiting
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Retina-Vitreous Associates Medical Group, Beverly Hills, California
Conditions: Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
The Impact of Melatonin Lotion on Sleep and Mental Health
Recruiting
The purpose of this study is to examine the effect that melatonin lotion has on sleep quality, the nervous system, and mental health. Melatonin is a hormone secreted by the brain that regulates sleep and might improve depression and anxiety symptoms. The goal is to determine whether melatonin in lotion form is an effective treatment for young adults with inadequate sleep and might improve mental health. Participants will fill out surveys, wear an actigraph (a wrist-worn device that measures slee... Read More
Gender:
ALL
Ages:
Between 18 years and 21 years
Trial Updated:
03/05/2025
Locations: University of Redlands, Redlands, California
Conditions: Sleep Problems, Depressive Disorder and Anxiety Disorders
Commercial or Open Source Closed Loop Impact on Pregnancy Study
Recruiting
The goal of this observational study is to better understand what happens when pregnant people with type 1 diabetes (T1D) use automated insulin delivery (AID) systems. The main questions this study aims to answer are: * What are the maternal and neonatal outcomes with AID system use in pregnancy? * What are the glycemic outcomes with AID system use in pregnancy? * What are the behavioral and emotional outcomes with AID system use in pregnancy? Researchers will compare pregnant people who use c... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Type 1 Diabetes, Pregnancy, High Risk, Insulin Dependent Diabetes, Pregnancy Related
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants
Recruiting
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses of KarXT + KarX-EC capsules versus KarXT capsules in healthy adult and elderly participants of Japanese ethnicity and to assess the effect of multiple doses of omeprazole on the exposure of xanomeline and trospium administered as KarXT + KarX-EC capsules in healthy adult participants.
Gender:
ALL
Ages:
Between 19 years and 90 years
Trial Updated:
03/05/2025
Locations: Cenexel ACT (Anaheim Clinical Trials), Anaheim, California
Conditions: Healthy Volunteers
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
Recruiting
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Dren Investigational Site, Northridge, California
Conditions: Alopecia Areata, Vitiligo
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Recruiting
This phase II trial tests the safety, side effects and effectiveness of epcoritamab and tazemetostat in treating patients with grade I-IIIa follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab is a bispecific monoclonal antibody that binds to two different antigens on the surface of cancer cells that may help the body's immune system attack the cancer and may interfere with the ability of the can... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR
Recruiting
This is a Phase 2, multi-site, two-period, open label randomized crossover (Period 1 and 2) study. Participants are randomized 1:1 to one of two 8-week on-demand product sequences - TFV douche then oral F/TDF or oral F/TDF then TFV douche - with a 2 to 4-week washout period in between. Domains of safety, acceptability, adherence, and PK/PD (sub-study only) are assessed for each product.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: UCLA CARE Center CRS, Los Angeles, California
Conditions: Tenofovir
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
Recruiting
A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 15 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 3 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Retina Vitreous Associates Medical Group, Beverly Hills, California
Conditions: Retinitis Pigmentosa, Choroideremia
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF
Recruiting
This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An early-stage patient... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
03/05/2025
Locations: Newport Native MD, Inc., Newport Beach, California
Conditions: Idiopathic Pulmonary Fibrosis, IPF